Avata Biosciences is thrilled to announce a significant funding milestone, having raised an impressive $110 million in its latest investment round. Formerly known as Sapient Therapeutics Ltd., Avata is a clinical-stage biopharmaceutical company dedicated to transforming the treatment landscape for patients afflicted by neurological diseases. With a pioneering approach that leverages synthetic cannabinoids and an innovative formulation process, Avata aims to broaden the reach of therapies to larger patient populations who currently face limited treatment options. The recent funding will be strategically directed towards advancing Avata's clinical trials, bolstering research and development efforts, and accelerating the pathway to FDA approval for its proprietary therapeutics. This injection of capital underscores investor confidence in Avata's vision to not only enhance the quality of life for individuals suffering from neurological conditions but also to establish a new paradigm in patient care. As the company forges ahead, it remains committed to advancing scientific discovery and delivering groundbreaking solutions that harness the potential of cannabinoids in managing complex neurological disorders. With this pivotal funding round, Avata Biosciences is poised to make significant strides in its mission, and we look forward to sharing more about our progress in the months to come.
Avata Biosciences Secures $110 Million in Funding to Revolutionize Treatment for Neurological Diseases
Recently funded 路 $110.0MPharmaceutical Manufacturing
Get the full Avata Biosciences company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
